Pharmala Biotech Holdings (XCNQ:MDMA) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XCNQ:MDMA Pharmala Biotech Holdings Inc XCNQ:MDMA
38 GF Score
Price C$0.25
GF Value C$0.25
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Pharmala Biotech Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Pharmala Biotech Holdings Valuation Rank Related Terms

XCNQ:MDMA
38GF Score
Pharmala Biotech Holdings Inc XCNQ:MDMA
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pharmala Biotech Holdings (XCNQ:MDMA) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued. The current stock price of C$0.25 is trading 0% below its estimated GF Value™ of C$0.25. GuruFocus considers Pharmala Biotech Holdings to be Fairly Valued.

Key valuation signals for XCNQ:MDMA:

  • Valuation Rank:
  • GF Value™: C$0.25 vs. price of C$0.25 (0% below fair value)
  • GF Score™: 38/100 with 4 warning signs

No single metric tells the full story. See the XCNQ:MDMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmala Biotech Holdings Business Description

Other Exchanges MDXXF:USA
Address 1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
38GF Score

Get the complete analysis for XCNQ:MDMA

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.25
Price
C$0.25
GF Value